# CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma

> **NCT04718883** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Shanghai Ming Ju Biotechnology Co., Ltd.** · enrollment: 59 (actual)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **BIOLOGICAL:** CD19-targeted Chimeric Antigen Receptor (CAR) T Cells

## Key facts

- **NCT ID:** NCT04718883
- **Lead sponsor:** Shanghai Ming Ju Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-01-13
- **Primary completion:** 2023-10-25
- **Final completion:** 2028-08-07
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2023-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04718883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04718883, "CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04718883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*